Literature DB >> 27488206

An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.

Jijie Li1, Kewei Yan2, Lisha Hou1, Xudong Du1, Ping Zhu1, Li Zheng3, Cairong Zhu4.   

Abstract

BACKGROUND AND OBJECTIVES: Pharmacokinetic/pharmacodynamic link models are widely used in dose-finding studies. By applying such models, the results of initial pharmacokinetic/pharmacodynamic studies can be used to predict the potential therapeutic dose range. This knowledge can improve the design of later comparative large-scale clinical trials by reducing the number of participants and saving time and resources. However, the modeling process can be challenging, time consuming, and costly, even when using cutting-edge, powerful pharmacological software. Here, we provide a freely available R program for expediently analyzing pharmacokinetic/pharmacodynamic data, including data importation, parameter estimation, simulation, and model diagnostics.
METHODS: First, we explain the theory related to the establishment of the pharmacokinetic/pharmacodynamic link model. Subsequently, we present the algorithms used for parameter estimation and potential therapeutic dose computation. The implementation of the R program is illustrated by a clinical example. The software package is then validated by comparing the model parameters and the goodness-of-fit statistics generated by our R package with those generated by the widely used pharmacological software WinNonlin.
RESULTS: The pharmacokinetic and pharmacodynamic parameters as well as the potential recommended therapeutic dose can be acquired with the R package. The validation process shows that the parameters estimated using our package are satisfactory.
CONCLUSIONS: The R program developed and presented here provides pharmacokinetic researchers with a simple and easy-to-access tool for pharmacokinetic/pharmacodynamic analysis on personal computers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27488206     DOI: 10.1007/s13318-016-0358-x

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  32 in total

1.  Dose-finding studies in clinical drug development.

Authors:  R Schmidt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.

Authors:  A Yassen; E Olofsen; R Romberg; E Sarton; L Teppema; M Danhof; A Dahan
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

3.  Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.

Authors:  Neal Thomas
Journal:  J Biopharm Stat       Date:  2006       Impact factor: 1.051

4.  Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood.

Authors:  A Raue; C Kreutz; T Maiwald; J Bachmann; M Schilling; U Klingmüller; J Timmer
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

Review 5.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

Authors:  B Meibohm; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

6.  Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats.

Authors:  P Vis; O Della Pasqua; M Kruk; D Martin; E Mocaër; M Danhof; R Jochemsen
Journal:  Eur J Pharmacol       Date:  2001-03-02       Impact factor: 4.432

7.  NM-Win: a personal computer-based Microsoft Windows front-end to NONMEM IV.

Authors:  J P Vielhaber; J S Barrett
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

8.  An adaptive optimal design for the E(max) model and its application in clinical trials.

Authors:  Sergei Leonov; Sam Miller
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

9.  Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Authors:  Chiaki Tanaka; Terence O'Reilly; John M Kovarik; Nicholas Shand; Katharine Hazell; Ian Judson; Eric Raymond; Sabine Zumstein-Mecker; Christine Stephan; Anne Boulay; Marc Hattenberger; George Thomas; Heidi A Lane
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

10.  Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.

Authors:  Facundo M Bertera; Marcos A Mayer; Javier A W Opezzo; Carlos A Taira; Guillermo F Bramuglia; Christian Höcht
Journal:  J Pharmacol Toxicol Methods       Date:  2007-05-04       Impact factor: 1.950

View more
  3 in total

1.  Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study.

Authors:  Joanna Sobiak; Matylda Resztak; Tomasz Pawiński; Paweł Żero; Danuta Ostalska-Nowicka; Jacek Zachwieja; Maria Chrzanowska
Journal:  Eur J Clin Pharmacol       Date:  2019-06-06       Impact factor: 2.953

2.  Predicting transdermal fentanyl delivery using physics-based simulations for tailored therapy based on the age.

Authors:  Flora Bahrami; René Michel Rossi; Thijs Defraeye
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  A Use of Tritium-Labeled Peat Fulvic Acids and Polyphenolic Derivatives for Designing Pharmacokinetic Experiments on Mice.

Authors:  Gennady A Badun; Maria G Chernysheva; Yury V Zhernov; Alina S Poroshina; Valery V Smirnov; Sergey E Pigarev; Tatiana A Mikhnevich; Dmitry S Volkov; Irina V Perminova; Elena I Fedoros
Journal:  Biomedicines       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.